Uncategorized Global Clinical Trials Software Market worth $ 4.13 billion by 2030 – Exclusive Report by InsightAce Analytic – Yahoo Finance
JERSEY CITY, N.J., Jan. 25, 2022 /PRNewswire/ — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Clinical Trials Software Market Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get the Sample Pages: https://www.insightaceanalytic.com/request-sample/1195
According to the latest research, the global clinical trials software market is valued at US$ 1.20 Billion in 2021, and it is expected to reach US$ 4.13 Billion by 2030, with a CAGR of 15.1% during the forecast period of 2022-2030. By region, North America dominated the global market with a share of 37% in 2021.
Clinical trials are an essential part of drug clinical research. Clinical trials are a major part of drug development processes and the discovery of new treatments and drugs for various diseases such as cancer and cardiovascular diseases. Advanced clinical trials software is widely used to improve data quality, management, and procedures of the research studies.
Increasing government funding for the development of clinical trial services, advancements in technologies, high demand for clinical trial management services is primarily driving the market growth. Rising R&D funding activities in clinical research, growing prevalence of chronic diseases, innovation of clinical trial planning & design services, developing healthcare infrastructure, and increasing use of cloud-based solutions by biopharma companies for clinical trial process automation are further likely to boost the market growth. There is a surge in clinical trial studies due to the rising prevalence of chronic diseases. Hence, biopharmaceutical companies adopt clinical trial management services to reduce process time and increase the efficiency and accuracy of clinical trials. Thus, it is expected to propel market growth opportunities in the next few years.
On the other side, the high cost of clinical trial software may hamper the market expansion over the forecast period.
Regionally, North America is expected to lead the global clinical trials software market during the forecast period (2022-2030), followed by Europe, owing to the increasing clinical R&D activities of pharma companies, fast adoption of cloud-based technologies, and rising prevalence of various diseases.
Request for ToC : https://www.insightaceanalytic.com/customisation/1195
Key market players operating in the clinical trials software market include Advarra, Antidote Technologies, Inc., ArisGlobal , AssistRx, athenahealth, Inc., Axiom Real-Time Metrics, BioClinica Inc. , BSI Business Systems Integration AG, Calyx , Castor EDC, Chronicles, Clario, Clarivate, ClinCapture, Clincase, Clinical Research, CLIRINX, Cloudbyz, Dacima Software Inc., Datatrak Int. , Florence HC , IBM , Instem , IQVIA , MasterControl Inc., Medidata Solutions Inc, MedNet Solutions Inc., Novatek International, Octalsoft , Openclinica, Oracle Corporation, Parexel International Corp., RealTime Software Solutions LLC, Reify Health, Inc., Signant Health, Statsols, TrialKit , Veeva Systems Inc., WIRB-Copernicus Group, and Other prominent players.
Key recent developments in the market:
In December 2021, Advarra (US), the market leader in clinical site technologies and research quality and compliance consulting services, launched Advarra Cloud. The next-generation platform broadens cloud deployment options for Advarra customers and delivers applications in an easy-to-use, fully managed environment.
In April 2021, Bioclinica (US) introduced the new source document management solution that combines advanced software with redaction and translation services to offer support to global research sites and trial management teams.
In April 2021, Calyx, the eClinical and regulatory solutions & services provider, released Calyx CTMS v15.0, an advanced clinical trial management system on Azure cloud technology to reduce risk and improve efficiencies in clinical development.
Curious about this latest version? Obtain Report Details @https://www.insightaceanalytic.com/report/global-clinical-trials-software-market-/1195
Global Clinical Trials Software Market, by Type of Deployment, 2022-2030 (Value US$ Mn)
Global Clinical Trials Software Market, by Type of Delivery, 2022-2030 (Value US$ Mn)
Global Clinical Trials Software Market, by Features of software, 2022-2030 (Value US$ Mn)
Global Clinical Trials Software Market, by End-Users, 2022-2030 (Value US$ Mn)
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Medical Device Manufacturers
Global Clinical Trials Software Market, by Region, 2022-2030 (Value US$ Mn)
Middle East & Africa
North America Clinical Trials Software Market, by Country, 2022-2030 (Value US$ Mn)
Europe Clinical Trials Software Market, by Country, 2022-2030 (Value US$ Mn)
Rest of Europe
Asia Pacific Clinical Trials Software Market, by Country, 2022-2030 (Value US$ Mn)
Australia & New Zealand
Latin America Clinical Trials Software Market, by Country, 2022-2030 (Value US$ Mn)
Rest of Latin America
Middle East & Africa Clinical Trials Software Market, by Country, 2022-2030 (Value US$ Mn)
Rest of Middle East & Africa
Why should buy this market research report:
To receive a exaustive analysis of the prospects for the global clinical trials software market
To receive an industry overview and future industry trends of the clinical trials software market
To analyze the clinical trials software market drivers and challenges
To get information on the clinical trials software market size (Value US$ Mn) forecast to 2030
To receive information on sgnificant investments, mergers & acquisitions in the clinical trials softwareindustry
Other Related Reports Published by InsightAce Analytic:
Global Site Management Organizations (SMO) Market
Global Clinical Trial Imaging Services Market
Global AI-Based Clinical Trial Solution Providers Market
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
InsightAce Analytic Pvt. Ltd.
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
View original content:https://www.prnewswire.com/news-releases/global-clinical-trials-software-market-worth–4-13-billion-by-2030—exclusive-report-by-insightace-analytic-301467454.html
SOURCE InsightAce Analytic Pvt. Ltd.
(Bloomberg) — The U.S. Department of Energy announced the loan of 13.4 million barrels of crude oil from its strategic reserve as part of a renewed effort by the Biden administration to contain oil prices that have surged to their highest level since 2014.Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapStocks Storm Back From 4% Rout to Close Higher: Markets WrapNvidia Quietly Prepares to Abandon $40 Billion Arm BidThis Red-Hot Housing Market Is Betting In
AT&T Inc. is rolling out the fastest consumer broadband offered by major internet providers in an aggressive move aimed at cable providers. Some 5.2 million customers could sign on. AT&T Communications CEO Jeff McElfresh is on "Bloomberg Markets."
(Bloomberg) — Lake Maracaibo is, in many ways, the unlikeliest of homes for a burgeoning shrimp farm industry. After a century of relentless oil drilling, much of it carried out in a reckless and haphazard manner in the final years, its surface is stained by petroleum slicks and choked with rusted-out rigs that stretch high into the sky.Most Read from BloombergStocks Get Crushed in Risk-Off Day as Bonds Rally: Markets WrapUAE Says New Attack Repelled as Yemen’s Houthis Vow MoreCrypto Crash Eras
HOUSTON (Reuters) -The chiefs of major U.S. oil companies Occidental Petroleum Corp and ConocoPhillips offered differing outlooks on the growth of U.S. oil output at a conference on Monday, as the industry rebounds from shutdowns during the first stage of the coronavirus pandemic. Oil prices have surged to seven-year highs in the last several weeks, with international benchmark Brent crude hitting nearly $90 per barrel, bolstered by tight worldwide supply and resurgent global demand. ConocoPhillips Chief Executive Officer Ryan Lance told an audience at the Argus Americas Crude Summit in Houston that he was bullish about markets as high oil prices "will persist for a while."
Free N95 masks available at local pharmacies, health centers
Foulger-Pratt is moving on from Landmark Mall. Jay Kelly, Foulger-Pratt’s vice president of development, announced last week that the 4.2 million-square-foot redevelopment of the 52-acre Landmark Mall property, to include a new Inova Alexandria hospital, is to be branded “West End.” It’s not a coincidence — Landmark Mall is, after all, located in Alexandria’s West End community.
Even if you've never heard of a company called Plaid, they may owe you part of a multi-million dollar lawsuit settlement.
(Bloomberg) — Oil prices rallied Tuesday after the biggest one-day tumble this year, with traders refocusing on the outlook for strong demand and the risk that a Russia-Ukraine conflict could disrupt supplies.Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapStocks Storm Back From 4% Rout to Close Higher: Markets WrapNvidia Quietly Prepares to Abandon $40 Billion Arm BidThis Red-Hot Housing Market Is Betting Interest Rates Will Never RiseBiden Bristles at F
The price of oil is at a seven-year high, above $88 dollars per barrel. Demand is rising and may surpass pre-pandemic levels by the end of 2022, the International Energy Agency forecast last week, as the global economy seems not to have been stalled by omicron. At the beginning of the pandemic, when travel seized up and oil demand evaporated, the price of oil crashed below zero for the first time.
(Bloomberg) — Qatar wouldn’t be able to significantly ramp up supplies of natural gas to Europe in the event of any disruption to Russian flows, according to three people familiar with the situation.Most Read from BloombergStock Rebound Attempt Fails as Clock Ticks on Fed: Markets WrapStocks Storm Back From 4% Rout to Close Higher: Markets WrapNvidia Quietly Prepares to Abandon $40 Billion Arm BidThis Red-Hot Housing Market Is Betting Interest Rates Will Never RiseBiden Bristles at Fox Inflatio
(Bloomberg) — The Biden administration has concluded that a global semiconductor shortage will persist until at least the second half of this year, promising long-term strain on a range of U.S. businesses including automakers and the consumer electronics industry. Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapNvidia Quietly Prepares to Abandon $40 Billion Arm BidStocks Storm Back From 4% Rout to Close Higher: Markets WrapThis Red-Hot Housing Market Is B
(Bloomberg) — Global banks are raising concerns to Chinese authorities about a plan to tighten rules on overseas stock listings, saying the draft rules are ambiguous and will expand Beijing’s regulatory reach outside the nation’s borders.Most Read from BloombergStocks Storm Back From 4% Rout to Close Higher: Markets WrapS&P 500 Slumps 2% Amid Fed, Russia-Ukraine Jitters: Markets WrapNvidia Quietly Prepares to Abandon $40 Billion Arm BidBiden Has ‘Great Meeting’ With European Leaders: Ukraine Up
ONEOK, Marathon Oil, and EOG are among the companies with the largest expected growth in free cash flow for the coming quarter.
Semiconductor inventories at manufacturers that need the chips fell to a median five days in 2021 from 40 days in 2019, a Commerce Department surve found.
Blackstone Group (NYSE: BX) is at it again. The private-equity giant is buying another real estate investment trust (REIT). This time, it's paying $3.7 billion to acquire Resource REIT, a non-traded REIT focused on owning apartment buildings.
Big Tech's massive growth during the COVID-19 pandemic reached its peak and its limit in 2021, and investors are now searching for safety as the outlook for the new year is looking glummer with every new earnings report.
The enthusiasm to find paying customers for artificial intelligence continues in China. AInnovation, a Chinese computer vision and machine learning startup backed by Kai-Fu Lee's Sinovation Ventures and SoftBank, is trying to automate China's massive manufacturing industry. Merely four years old, the startup has filed to go public in Hong Kong, and its prospectus is offering a rare glimpse into the commercial viability of smart manufacturing, which is a key part of China's industrial blueprint for the next few years.
(Bloomberg) — Shale-oil companies are using almost all of the fracking equipment and crews available as exploration expands, accelerating cost inflation and pointing to worsening supply-chain disruptions across the industry.Most Read from BloombergStocks Storm Back From 4% Rout to Close Higher: Markets WrapBiden Has ‘Great Meeting’ With European Leaders: Ukraine UpdateChina’s ‘Little Giants’ Are Its Latest Weapon in the U.S. Tech WarUAE Says New Attack Repelled as Yemen’s Houthis Vow MoreHong K
(Reuters) -Halliburton Co's fourth-quarter adjusted profit doubled from a year earlier, it said on Monday, beating analysts' forecasts and prompting the oilfield services company to lift its dividend following a rebound in crude and natural gas prices. U.S. oil prices rose more than 50% last year and have made a strong start to 2022, hovering around $85 a barrel, thanks to the global economic recovery from the coronavirus pandemic and supply cuts by producer group OPEC. That has encouraged producers to ramp up drilling activity, with the U.S. rig count rising 68% year-over-year to 586 at the end of the fourth quarter, according to Baker Hughes data.
Instead of curbing prices, the producers’ inability to increase production as promised has become a reason for traders to bet on higher prices.